Novartis completes divestment of ‘front of eye’ ophthalmology assets

Novartis completes divestment of ‘front of eye’ ophthalmology assets
arcticnovartis

  • Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapies
  • Novartis advances strategy of focused portfolio and prioritized therapeutic areas for future growth

Basel, September 29th, 2023 — Novartis today announced that it has completed its divestment of ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to USD 2.5 billion, consisting of 1.75 billion in upfront cash, plus potential add

/by
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe

Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
arcticnovartis

  • Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in Europe
  • Decision based on evidence from extensive analytical characterization demonstrating similarity of biosimilar with reference biologic, in addition to Phase I and confirmatory Phase III studies.
/by
Novartis confirms Sandoz Spin-off for October 4, 2023

Novartis confirms Sandoz Spin-off for October 4, 2023
arcticnovartis

  • Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023
  • Sandoz to be included in key Swiss market indices
  • Investment grade credit rating for Sandoz confirmed: Moody’s, Baa2; S&P, BBB
  • Debt financing of USD 3.75 billion (in various currencies) secured for Sandoz, supported by USD 1.25 billion revolving credit facility
  • Spin-off to be completed by way of a 1:5 distribution of Sandoz shares to Nov
/by
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
arcticnovartis

  • Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received first line treatment with Lutathera® in combination with long-acting octreotide, versus high-dose long-acting octreotide alone1,2
  • Lutathera is the first radioligand therapy (RLT) to demonstrate clinically meaningful benefit in a
/by
Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.

Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
weberfr8

/by
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab

Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
arcticnovartis

  • Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical data
  • Breast and gastric cancers are among most common types of cancer, accounting together for nearly half a million new cases every year in Europe alone1,2
  • Sandoz is committed to accelerating access to potentially life-changing treatments and continues to strengthen its oncology and supportive care portfolio

Basel, September 18, 2023 —

/by
Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu

Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
arcticnovartis

  • Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.
  • Die Aktionärinnen und Aktionäre stimmen ausserdem einer Herabsetzung des Aktienkapitals im Zusammenhang mit dem Spin-off zu.
  • Die Aktionärinnen und Aktionäre von Novartis und Inhaberinnen und Inhaber der Novartis ADR erhalten durch die Ausschüttung einer Sachdividende eine Sandoz Aktie für jeweils fünf Novartis Aktien oder ein Sandoz ADR für jeweils fünf Novartis ADRs.
/by